Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Theravance Bio Ord (TBPH)
Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Theravance Bio: Q4 Earnings Snapshot

Theravance Bio: Q4 Earnings Snapshot

TBPH : 9.44 (-0.32%)
Theravance Bio: Q3 Earnings Snapshot

Theravance Bio: Q3 Earnings Snapshot

TBPH : 9.44 (-0.32%)
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023

/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2023 financial results and provide a business update after market close...

TBPH : 9.44 (-0.32%)
Theravance Biopharma to Participate in an Upcoming Investor Conference

/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference...

TBPH : 9.44 (-0.32%)
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic...

TBPH : 9.44 (-0.32%)
Theravance Bio: Q2 Earnings Snapshot

Theravance Bio: Q2 Earnings Snapshot

TBPH : 9.44 (-0.32%)
Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 20221 Q2 2023 YUPELRI total retail TRx and new to product TRx...

TBPH : 9.44 (-0.32%)
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023

/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2023 financial results and provide a business update after market...

TBPH : 9.44 (-0.32%)
Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that the US Food and Drug Administration...

TBPH : 9.44 (-0.32%)
Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates

Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.

TBPH : 9.44 (-0.32%)
ITRM : 1.3000 (+4.84%)
LRMR : 11.35 (-1.30%)
VTRS : 12.59 (+1.78%)

Barchart Exclusives

Gold: Is $2,000 a Bottom?
Gold reached a new record high in 2023 and was the only precious metal with a significant gain last year. While the $2,000 level was a technical resistance level over the past years, it has become technical support in 2024. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar